Select publications
Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. Anticancer Drugs 2007;18(1):7-15. Abstract
Hecht J et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Proc ASCO GI Cancers Symposium 2006;Abstract 237.
Hecht J et al. ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Proc ASCO 2004;Abstract 3511.
Hedrick E et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). Proc ASCO 2006;Abstract 3536.
Lenz HJ. Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 2006;20(5 Suppl 2):5-13. Abstract
Melichar B et al. Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer 2006;[Epub ahead of print]. Abstract
Patel DD, Goldberg RM. Cetuximab-associated infusion reactions: Pathology and management. Oncology (Williston Park) 2006;20(11):1373-82. Abstract
Peeters M et al. A Phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Proc AACR 2006;Abstract CP-1.
Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006;6(2):118-24. Abstract
Saltz LB et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Proc ASCO 2005;Abstract 3508.
Skillings JR et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy. Proc ASCO 2005;Abstract 3019.
Wainberg Z, Hecht JR. A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;5(5):363-7. No abstract available
